Cytokinetics set to battle Bristol Myers as FDA approves heart drug [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
The Food and Drug Administration has approved a new treatment for an inherited form of heart failure in a decision that also gives the medicine's maker, Cytokinetics, the first U.S. approval in its nearly three-decade history. The agency on Friday approved Cytokinetics' Myqorzo for adults with obstructive hypertrophic cardiomyopathy, a potentially deadly condition that impairs the heart's ability to pump blood. The drug has specifically been cleared to help improve functional capacity and symptoms in patients whose disease severity is categorized as “Class II” or Class III.” It will be available in the second half of January, according to the company. Myqorzo's prescribing information includes somewhat less restrictive risk mitigation measures than what's mandated for people taking Bristol Myers Squibb's Camzyos , the only other available medication for the disease. Wall Street analysts and investors were closely watching whether Myqorzo's' risk management protocol might be diffe
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 12/19/25 - Form 8-K
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- CYTK's page on the SEC website